natgillin/translations-raw huggingface dataset:
It is possible for the controller to be contained in the parts on the diaper and/or in the parts of the diaper accessory not on the diaper. 
Postupak prema jednom od zahtjeva 1 do 9, kod kojeg je modul pelene (2) postavljen reverzibilno ili ireverzibilno na pelenu (1),
For example, for the treatment of glaucoma, a cream, gel, spray, lotion, ointment, stick applicator, foam, film, or an adhesive formulation for example containing latanoprost in an amount of about 0.1 to 40 wt % of the composition is applied to the upper eyelid. 
Pripravak za uporabu u skladu s patentnim zahtjevom 1, naznačen time, da je navedeni pripravak pripravljen u obliku kreme, gela, losiona, spreja, pjene, filma, trake, masti, gipsa, aplikatora za kapke ili ljepila za nanošenje na gornji i / ili donji kapak ljudskog pacijenta.
The method as claimed in claim 12 comprising electrically insulating the electro-discharge nozzle from a water pump by an electrically insulating coupling, the water pump pressurizing the water to create a high-speed waterjet through the exit orifice. 
Metoda prema zahtjevu 12, koja obuhvaća električnu izolaciju elektroerozijske mlaznice (2b) od vodene pumpe (33) putem spojke za električnu izolaciju, s tim da vodena pumpa (33) stavlja vodu pod tlak u svrhu stvaranja mlaza vode kroz izlazni otvor (2c).
System according to claim 1 comprising a connected device called “float valve” comprising: 
Sustav prema patentnom zahtjevu 1, koji sadrži plutajući ventil koji sadrži:
The suspension which forms is filtered, washed with water (0.5 ml) and dried under high vacuum to yield the titled compound. 
Nastalu suspenziju se profiltrira, ispere s vodom (0,5 ml) i osuši pod visokim vakuumom, čime se dobije naslovni spoj.
More preferably, at least about 90%, preferably 95%, of the coated micropellets have a particle size of about 100 um to about 650 um, most preferably, about 200 um to about 500 um. 
Još povoljnije, barem 90%, povoljnije 95%, obloženih mikropeleta ima veličinu čestica od oko 100 um do oko 650 um, najpovoljnije je od oko 200 um do oko 500 um.
It was dried at reduced pressure to obtain 0.83 g of an orange-yellow oil corresponding to the product of interest. 
Osuši se pod smanjenim tlakom, čime se dobije 0,83 g narančasto-žutog ulja koje odgovara željenom proizvodu.
The composition according to any one of claims 1-4, which further comprises at least one hydrophilic gelling agent selected from glucose, modified starch, methyl cellulose, carboxymethyl cellulose, propyl cellulose, hydroxypropyl cellulose, carbopol(RTM) polymers, alginic acid, sodium alginate, potassium alginate, ammonium alginate, calcium alginate, agar, carrageenan, locust bean gum, pectin, and gelatin. 
Kompozicija za primjenu prema patentnom zahtjevu 1 ili 2, koja dalje sadrži najmanje jedan hidrofilni agens za geliranje odabran od glukoze, modificiranog škroba, metil celuloze, karboksimetil celuloze, propil celuloze, hidroksipropil celuloze, karbopol (RTM) polimera, alginske kiseline, natrij alginata, kalij alginata, amonij alginata, kalcij alginata, agara, karagenana, karuba gume, pektina, i želatina.
The composition for use according to claim 13, wherein crenolanib or a salt thereof is provided as a single agent or in combination with another chemotherapeutic agent for treatment of pediatric subject with the acute myeloid leukemia (AML). 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 13, pri čemu se crenolanib ili njegova sol osigurava kao jedini agens ili u kombinaciji s drugim kemoterapijskim agensom za liječenje pedijatrijskog subjekta s akutnom mijeloičnom leukemijom (AML).
A method for making, in a ready for cooking condition, non pre-cooked fresh-pasta lasagne, said method comprising the steps of providing a first and second thin pasta layers each having a thickness less than 12 millimetrers, metering on su stantially the overall top surface of said first pasta layer a very soft, nearly liquid material and integral meat piece mixture, overlapping on said first pasta layer said second pasta layer, sealing on the four sides thereof said stuffing mixture containing first and second overlapped pasta layer, to provide a two pasta layer stuffed sealed unit, pasteurizing said unit, and overlapping a number of said units while simultaneously hot metering between each pair of overlapping said units bechamel and/or other sauces. 
Postupak pripreme, u stanju spremnom za kuhanje, lazanja od svježe tjestenine koje nisu prethodno kuhane, taj postupak obuhvaća korake pribavljanja prvog i drugog tankog sloja tjestenine od koji svaki ima debljinu manju od 1.2 milimetara, raspodjelu vrlo mekanog, gotovo tekućeg materijala i integralne smjese mesa na u biti cijelu gornju površinu prvog sloja tjestenine, preklapanje drugog sloja tjestenine na prvi sloj tjestenine, zatvaranje četiri strano preklopljenog prvog i drugog sloja tjestenine u kojima je smjesa za punjenje, tako da se dobije komad napunjene zatvorene dvoslojne tjestenine, pasteriziranje tog komada i slaganje više takvih komada uz istodobno vruće oblaganje bešamelom i/ili drugim umacima između svakog para složenih komada.
a wireline connector secured to the said end, outside the hollow housing. 
- < konektor (44) žičane veze je na navedenom kraju, izvan šupljeg kućišta.
an HC-FR4 comprising the amino acid sequence of SEQ ID NO:24, and a light chain variable domain comprising: 
HC-FR1 koji sadrži aminokiselinsku sekvencu od SEQ ID NO:25; i ima slabi lanac (LC) koji obuhvaća:
Pharmaceutical composition for the preparation of infusion solutions of antimicrobial preparations, its production process 
FARMACEUTSKA MJEÅ AVINA ZA PRIPREMU INFUZIJSKIH OTOPINA ANTIMIKROBNIH PRIPRAVAKA, NJEZIN PROIZVODNI PROCES
Moreover, as the problem relates to the accidental contamination of extruded PMMA and/or ABS by traces of crosslinked PMMA, micronization would have to be carried out on the entire material, also comprising the non-crosslinked fraction, with a further cost burden. 
Osim toga, kao problem koji se odnosi na slučajnu kontaminaciju ekstrudiranog PMMA i/ili ABS s tragovima umreženog PMMA, mikronizacija treba biti izvedena na cijelom materijalu, uključujući dakle i frakciju koja nije umrežena, s daljnjim opterećenjem troškovima. HR P20090115 T3
The compound according to claim 1, wherein ring B and the pyrimidine to which it is fused form a ring system selected from wherein 
Spoj prema zahtjevu 1, naznačen time da prsten B i pirimidin na koji je kondenziran tvore prstenasti sustav odabran od N
A compound selected from the group consisting of: 
Spoj patentnog zahtjeva 1 izabrano iz grupe koja se sastoji od
wherein the supporting structure and the formwork skin are each a plastic material. 
pokrov oplate (6), odvojivo spojen s nosivom strukturom (4);
After concentration, the residue was taken up in DCM and saturated aqueous NaHCO3 was added. 
Nakon koncentriranja ostatak se preuzme u DCM, te se doda zasićena vodena otopina NaHCO;.
Tank according to claim 15 where the tank is the coffee powder tank of a coffee machine. 
Rezervoar u skladu s patentnim zahtjevom 15, naznačen time što navedeni rezervoar je rezervoar za kavu u prahu stroja za kuhanje kave.
an on-load tap changer connected with the control winding and constructed in accordance with claim 1 . 
regulacijske sklopke pod opterećenjem (1) koja je povezana s regulacijskim namotom (20) i izvedena u skladu s bilo kojim od patentnih zahtjeva 1 do 4.
Excipients not included in Lozenge formulation:— Formulation (kg) 
Inertni punitelji koji nisu uključeni u formulaciju tableta: Formulacija (kg)
Device according to claim 1, wherein the limit switch comprises a movable abutment, the pusher comprising a bearing surface configured for resting on the abutment only when the limit switch is in the sealing position. 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time, da granična sklopka ima pomični graničnik (37), a potiskivač (10) ima nosivu površinu (40) koja je prilagođena da se oslanja samo na graničniku kada je granična sklopka u zatvorenom položaju.
is selected from the structures: where the wavy line indicates the site of attachment; and 
Spoj, naznačen time, da je odabran iz skupine koju čine:
Finally, 0.1 eq of azo-bisisobutyronitrile (AIBN) is added and the mixture is heated at 70°C for approx. 6 hours. 
Konačno, dodan je 0.1 ekvivalent azo-bisizobutironlitrila (AIBN) I smjesa je zagrijavana pri 70 "C približno 6 sati.
The combined extract was cooled to 0 to 5°C., acidified slowly to a pH below 1.0 with concentrated HC1 and extracted with ethyl acetate (4 X 1 1. 
Spojeni ekstrakt se ohladi na 0 do 5C, zakiseli se lagano na pH ispod 1.0 sa koncentriranom HC1 i ekstrahira se sa etilacetatom (4x1 1.
each Ra4 independently of one another is a group, optionally substituted by one or more, identical or different Rb4 and/or Rc4, selected from among C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C3-7cycloalkyl, C4-7cycloalkenyl, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl; 
svaki Ra4 međusobno neovisno označava skupinu, opcionalno supstituiranu s jednom ili više, istih ili različitih Rb4 i/ili Rc4, odabranih između sljedećih: C1-6alkil, C2-6alkenil, C2-6alkinil, C1-6haloalkil, C37cikloalkil, C47cikloalkenil, C610aril, 5-10-člani heteroaril i 310-člani heterociklil;
The apparatus according to claim 1, further comprising an electrical power supply from grid, rechargeable batteries or solar panels, alone or in mutual combination. 
Uređaj sukladno bilo kojem od prethodnih Zahtjeva opremljen dovodom električne energije iz mreže, punjivih baterija ili solarnih panela, odvojeno ili u kombinaciji.
The orodispersible effervescent tablet of claim 2, wherein said salt of at least one pharmacologically acceptable acid that can release a gas with a further acid is a salt of carbonic acid. 
Orodisperziblna pjenušava tableta u skladu s patentnim zahtjevom 1, naznačena time što je sol farmaceutski prihvatljive kiseline koja u vodenom okolišu može otpustiti plin s kiselinom NaHCO3, Na2CO3, KHCO3, K2CO2, CaCO3, ili njihova smjesa.
In case the pyrazine derivative contains two hydroxyhydrocarbyl residues, it is preferred that these residues are in the para or meta positions. 
U slučaju da derivat pirazina sadržava dva hidroksihidrokarbilna ostatka, poželjno je da su ti ostaci u para ili meta položajima.
This application claims the benefit of the filing date of U.S. provisional patent application Ser. 
Broj objave europske prijave patenta: EP 2152748 A1 Datum objave europske prijave patenta:
Preferably R2 is hydrogen or (1-3C)alkyl. 
R* je najpoželjnije vodik ili (1-3C)alkil.
expressing the recombinant VKORC1 and VKD protein of step (b) with an increased secretion rate compared to the expression of the rVKD protein in a host organism which does not co-express rVKORC1; and 
(c) eksprimiranje nukleinskih kiselina iz koraka (a) i (b); pri čemu se količina sekrecije rekombinantno eksprimiranog VKD-proteina uglavnom povećava u usporedbi s ekspresijom rVKD-proteina u organizmu domačina, koji ne ko-eksprimira VKORC1.
The epoxidation reaction can be carried out using conditions and reagents well known to the skilled chemist, see for example J. 
Reakcija epoksidacije se može provesti korištenjem uvjeta i reagensa dobro poznatih iskusnim kemičarima, vidi na primjer J.
the citrate buffer has a concentration of about 20 mM, wherein the pH of the formulation is about 6.5, and 
citratni pufer ima koncentraciju od 20 mM tako da pH formulacije iznosi 6.5, i naznačena time što navedeno vWF vezivo sadrži SEQ ID NO: 1.
The process according to claim 20, characterised in that the Group II or Group III salt(s) of a C8 to C24 aliphatic monocarboxylic acid employed in step (a) features a d98 of 20 microns according to screen residue measurement performed with 20 microns DIN screens. 
Postupak prema bilo kojem od zahtjeva 1 do 10, naznačen time da sol odnosno soli Skupine II ili Skupine II C8 do C24 alifatske monokarboksilne kiseline koja se koristi u koraku (a) se primjenjuju u obliku suhog praha, te poželjno imaju dog od 20 mikrona prema mjerenju ostatka prosijavanja provedenog sa DIN sitima od 20 mikrona.
TLK199 is currently being evaluated in a Phase II clinical trial for the treatment of MDS. Interim results from this trial, reported at the 2004 and 2005 American Society of Hematology meetings, demonstrated that TLK199 was well tolerated and resulted in multilineage hematologic improvement. 
TLK 199 je sada procijenjen u Fazi II kliničkog ispitivanja za tretman MDS, Privremeni rezultati ovog ispitivanja, predočeni na sastancima 2004 i 2005 Američkom društvu hematologa, pokazuju da je TLK 199 vrlo tolerantan 1 rezultira
The surface relief may be embossed in the surface of the first and/or second outer part. 
Plošni reljef može biti graviran u površini prvog i/ili drugog vanjskog dijela.
Dosage form for use according to any of embodiments 7 to 11, wherein the application fluid is selected from the group comprising water and an aqueous saline solution, preferably an aqueous NaCl solution, more preferably an aqueous 0.9% (weight/volume) NaCl solution. 
Oblik doziranja za uporabu prema bilo kojem od zahtjeva 5 do 9, naznačen time da je tekućina za primjenu odabrana iz skupine koja sadrži vodu i vodenu fiziološku otopinu, poželjno vodenu otopinu NaCI, poželjnije 0.9% (masa/volumen) vodenu otopinu NaCI .
a length direction of the separate and flexible tongue (3) extends parallel with said edge and/or groove; 
smjer duljine odvojenog i savitljivog jezika (3) proteže se paralelno s navedenim rubom i/ili žljebom;
The composition for the use according to claim 10, wherein the composition is for being used in combination with an additional therapeutic agent selected from an immunomodulatory agent, a hormonal agent, a chemotherapeutic agent, an anti-angiogenic agent, an apoptotic agent, a second antibody that binds to and inhibits an inhibitory KIR receptor, an anti-infective agent, a targeting agent and an adjunct compound, wherein said additional therapeutic agent is for being administered as a single dosage form together with said first antibody or as a separate dosage form. 
Oblik prema zahtjevu 43, sadrži lijek koji se koristi u kombinaciji s odgovarajućim dodatnim terapijskim sredstvom izabranim između imunomodulatornog sredstva, hormona, kemoterapijskog sredstva, anti-angiogeničnog sredstva, apoptotičnog sredstva, drugog protutijela koje veže 1 inhibira inhibitorni KIR receptor, anti-infektivnog sredstva, ciljnog sredstva ili dodatnog spoja gdje se to dodatno terapijsko sredstvo primjenjuje bolesniku kao jedan dozirni oblik zajedno s protutijelom, ili kao posebni dozirni oblik.
An antibacterial agent comprising an ionic nanostructured complex formed by proteins and/or polypeptides, carbohydrates, salts of alkali and alkaline-earth metals and iodine intercalated into them wherein the proteins and/or polypeptides of the ionic nanostructured complex contain at least one chain-terminal amino acid with electron-donor functional groups. 
HR P20180075 T1 PATENTNI ZAHTJEVI Antibakterijsko sredstvo, naznačeno time, da obuhvaća ionski nanostrukturirani kompleks koji je sastavljen od proteina i/ili polipeptida, ugljikohidrata, soli alkalijskih metala ili soli zemnoalkalijskih metala te joda koji se umeće u unutrašnjost njihovih struktura, pri čemu proteini i/ili polipeptidi od ionskog nanostrukturiranog kompleksa, sadrže najmanje jedan završetak amionokiselinskog lanca s funkcionalnim elektron-donorskim skupinama.
The assembly of claim 1, wherein at least one of the rollers includes a roller body, and a roller sleeve mounted on the roller body so as to generally encompass the roller body and movable angularly thereabout. The assembly of claim 1, wherein the crusher assembly is a bucket including a scoop portion adjacent said inlet to aid in delivering material to said passage. 
Sklop u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što najmanje jedan od valjaka (20) ima tijelo valjka (23), te tuljac valjka (24), tako ugrađen na tijelo valjka da općenito oklapa tijelo valjka i pokretan je u kutnom smislu.
The method according to any one of embodiments 1, 3, 4 and 8 to 36, wherein the glucose fermenting microorganism is a Lactococcus lactis. 
Postupak prema bilo kojem od zahtjeva 1 do 7, naznačen time što mikroorganizam koji fermentira glukozu je bakterija mliječne kiseline, kao što je Lactococcus lactis.
In one embodiment the first proximal end and the second proximal end are within a short repeat. 
Polipeptid u skladu s patentnim zahtjevom 7, naznačen time što je drugi proksimalni kraj unutar ponavljanog dijela II toksina B.
is substituted cycloheteroalkyl, wherein the substituents are selected from the group consisting of aryl, substituted aryl, alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, cycloalkyldiyl, substituted cycloalkydiyl,, substituted cycloheteroalkyldiyl, and hydroxyl; 
je supstituirani cikloheteroalkil, pri čemu se supstituenti biraju iz skupine koju čine aril, supstituirani aril, alkil, supstituirani alkil, arilalkil, supstituirani arilalkil, cikloalkildiil, supstituirani cikloalkildiil, supstituirani cikloheteroalkildiil, i hidroksil;
173-176 describes the chemoselective action of isosorbide-2,5-dinitrate. 
173-176 opisuje kemoselektivno djelovanje izosorbid-2,5-dinitrata.
“cycloalkyl” means any mono- or bi-cyclic, non-aromatic, carbocyclic group containing from 3 to 10 ring members, 
"cikloalkil" označava bilo koju mono- ili bi-cikličku, ne-aromatsku, karbocikličku skupinu koja se sastoji od 3 do 10 članova prstena,
obtaining an aqueous pharmaceutical solution of glatiramer acetate and mannitol; filtering the aqueous pharmaceutical solution at a temperature of above 0°C to 17.5°C to produce a filtrate; and 
dobivanje vodene farmaceutske otopine glatiramer acetata i manitola; (ii) filtriranje vodene farmaceutske otopine pri temperaturi od iznad 0°C do 17,5°C da se proizvede filtrat; i
The compound according to claim 1, wherein the compound is of formula VI: or a tautomer, enantiomer or salt thereof, wherein: 
Spoj u skladu s patentnim zahtjevom 1, s formulom VI: [image], ili njegov tautomer, enantiomer ili sol, naznačen time što:
Field of application 
Datum podnošenja zahtjeva u HR:
the at least one turning vane (201) having single unit connections pieces (202) at each end of the hollow turning vane (201); 
- <elemente za spajanje (202) na svakom kraju šupljih rotirajućih lopatica (201), za povezivanje lopatica (201) sa sustavom cijevi za fluide; i
For which purpose, microprocessor 6b is designed to trip switch 35 (via control signal TSOG), thus changing the threshold of comparators 33, 34, and to check the output level of AND logic gates 30, 31 is disabled. 
Za ovu svrhu, mikroprocesor 6b je projektiran tako da djeluje na prekidač 35 (putem upravljačkog signala TSOG), na taj način mijenjajući prag uspoređivača 33, 34 i da bi provjerio da li je izlazna razina I logičkih vrata 30, 31 onemogućena.
The mechanism for absorbing kinetic energy in shock absorbers and barrier ends for roadways, according to claim 5, characterized in that two or more deformable metallic (2) profiles are attached to the same guide profile (6). 
Sustav u skladu s patentnim zahtjevom 4, naznačen time što su dva ili više deformabilni profila (2) osigurani na isti vodeći profil (6).
The extended release tablet formulation of claim 4, wherein the water swelling polymer, which is not pregelatinized starch or an anionic polymer, is hydroxypropylmethylcellulose, and wherein the content of hydroxypropyl methylcellulose in the matrix is from 10 wt.-% to 75 wt.-%, and preferably from 25 wt.-% to 65 wt.-%. 
Formulacija tablete produljenog oslobađanja u skladu sa zahtjevom 4, naznačena time, da u biti neutralan polimer je hidroksipropilmetilceluloza, te pri čemu sadržaj hidroksipropilmetilceluloze u matrici je od oko 10 mas. % do oko 75 mas. %, te je povoljnije od oko 25 mas. % do oko 65 mas. %.
The nitro group is reduced to the amine, and the diamine is treated with diethyl oxalate to give the quinoxalindione. 
Nitro skupina se reducira do amina, i diamin se tretira dietil-oksalatom čime se dobiva kinoksalindion.
The composition of any of the preceding claims, wherein the improvement further includes a decrease in audiogenic seizures. 
Pripravak namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što dolazi do poboljšanja socijalnih vještina kod osobe.
2(a), as well as a blank 70 of the inner shell 6, see FIG. 2(b). In the embodiment, both blanks are made from cardboard of a usual thickness, e.g. in the weight range from 180 g/m2 to 290 g/m2. 
102) i/ili unutarnja ljuska (6; 96: 106, 107) savijene iz odgovarajućeg prireza razvijenog oplošja (60; 70; 84, 86), koji prirez je načinjen od kartona koji se nalazi u području mase od 180 g/m? do 290 g/m".
The pharmaceutical composition for the use of claim 16, wherein the viral disease is human papilloma virus. 
Farmaceutski pripravak za primjenu prema zahtjevu 16, naznačen time, što je virusno oboljenje ljudski papilomavirus.
Although rapamycin shares structural homology with the immunosuppressant tacrolimus (FK506) and binds to the same intracellular binding protein in lymphocytes, rapamycin and tacrolimus have been shown to have different mechanisms of immunospressive action. 
Iako rapamicin pokazuje strukturnu homologiju s imunosupresivom takrolimusom (FK506) i veže isti unutarstanični vezni protein u limfocitima, pokazalo se da rapamicin i takrolimus HR P20070383 T3 imaju različite mehanizme imunosupresivnog djelovanja.
The pharmaceutical kit according to claims 15 or 16, wherein the content of at least one of the first and the second container is lyophilised. 
Farmaceutski komplet u skladu s patentnim zahtjevom 14, naznačen time što su i prvi i drugi spremnik štrcaljke za jednokratnu uporabu.
Preferably the removable aseptic seal is connected to the outer wall at the bottom of the base unit. 
Odvojiva aceptična brtva spojena je ponajprije na vanjsku stijenku pri dnu osnovne jedinice.
The floor structure is also shown in Fig. 4. 
Građa poda je također prikazana slikom 4,
is modified to exhibit less immunogenicity as compared to the same drug in unmodified form. The method of claim of any one of claims 1 to 4, further comprising: 
Postupak prema zahtjevu 8, naznačen time što lijek je lijek modificiran tako da pokazuje manju imunogenost u usporedbi s istim lijekom u nemodificiranom obliku.
A removable cover covers the opening. 
Pokrov, koji se može odstraniti, pokriva otvor.
3.0 In another aspect, the compound of Formula (IA) as an anhydrate in crystalline form is characterised by an XRPD pattern that is substantially as shown in FIG. 
Spoj prema bilo kojem od zahtjeva 1 do 2, gdje kristalni oblik spoja je naznačen time što ima XRPD uzorak koji izgleda kao što je prikazano na Slici 2.
The first set of values of the variables of Structural Formula (I) is as follows: 
(33) Država ili organizacija podnošenja prve prijave: US
According to one embodiment of the invention the B2-agonist is formoterol, in particular formoterol fumarate. 
Kombinacija sukladno patentnom zahtjevu 5, naznačena time, da je B2 agonist formoterol fumarat.